BLOOD AND SOURCE PLASMA BIOLOGICAL PRODUCT DEVIATION CODES FY17

CBER enters the fourth level detail code (e.g., A, B, C) into the database as standardized remarks to further describe some of the codes, in particular miscellaneous codes. These codes are not included on the BPD report form.

PD/DS/DD DONOR ELIGIBILITY

PD-**-** POST DONATION INFORMATION

PD-10-** Miscellaneous

PD-10-01 Other

PD-11-** Testing {information provided by donor or third party, includes true positive and false positive test results; use PD-13 for a reactive test obtained post donation; use MI codes for confirmed positives if testing performed at your facility}

PD-11-01 Other

PD-11-03 Tested reactive for Hepatitis B prior to donation

PD-11-05 Tested reactive for Hepatitis C prior to donation

PD-11-07 Tested reactive for HIV prior to donation

PD-11-09 Tested reactive for HTLV prior to donation

PD-11-11 Tested reactive for sexually transmitted disease prior to donation

PD-11-13 Tested reactive for hepatitis not specified or elevated liver enzymes, prior to donation

PD-11-14 Tested reactive at another center, specific testing unknown

PD-12-** Behavior/History

PD-12-01 Other {includes type of behavior or history unknown or not specified; unacceptable address; rape; donor unreliable, for example mental status questionable or donor unable to comprehend donor history questions; donor did not meet specifications for TRALI risk mitigation (e.g., history of pregnancy)}

PD-12-02 History of hepatitis not specified

PD-12-03 History of jaundice

PD-12-04 History of Hepatitis B

PD-12-05 History of Hepatitis C

PD-12-06 Sexually transmitted disease

PD-12-07 Intimate contact with risk for a relevant transfusion-transmitted infection - sexually transmitted disease

PD-12-13 Non-specific intimate contact with risk for a relevant transfusion-transmitted infection {includes contact with an individual who was deferred by another center, on a national deferral list, or tested reactive for an unknown viral marker}

PD-12-14 Male donor had sex with another man

PD-12-15 Female had sex with a man who had sex with another man

PD-12-16 IV drug use not prescribed by a doctor {includes taking illegal drugs by needle, e.g., IM}

- PD-12-17 Sex partner used IV drugs not prescribed by a doctor
- PD-12-18 Non-IV-drug use {includes taking illegal drugs by route other than needle}
- PD-12-19 Sex partner used non-IV drugs
- PD-12-20 Donor lived in or immigrated from an HIV Group O risk area
- PD-12-21 Sex partner lived in or immigrated from an HIV Group O risk area
- PD-12-22 Exchanged sex for drugs or money
- PD-12-23 Sex partner exchanged sex for drugs or money
- PD-12-28 Donor received transfusion
- PD-12-29 Donor received tissue allograft or transplanted organ
- PD-12-36 Travel to malaria endemic area/history of malaria
- PD-12-37 History of disease {donor was aware of condition or disease **prior** to donation; does not include diseases that do not affect the safety, purity, or potency of the product e.g., heart disease, hemochromatosis, autoimmune disorders, such as Rheumatoid Arthritis, Lupus; history of surgery is reported under PD-12-28 only if blood or blood products were received during surgery or under PD-12-29 if donor received tissue allograft or transplanted organ}
 - A Babesia
 - B West Nile Virus
 - C Chagas
 - E Fever/Diarrhea
 - F Infection
 - G Lyme disease
 - H Mononucleosis/Epstein-Barr virus
 - I Blood Disorder
 - J Von Willebrand disease
 - K Idiopathic Thrombocytopenic Purpura (ITP)/Thrombotic

Thrombocytopenic purpura (TTP)

- L Unknown/not specified
- PD-12-40 Risk factors associated with Creutzfeldt-Jakob Disease brain surgery
- PD-12-41 Risk factors associated with Creutzfeldt-Jakob Disease family history
- PD-12-42 Risk factors associated with Creutzfeldt-Jakob Disease (vCJD) travel
- PD-12-43 Risk factors associated with Creutzfeldt-Jakob Disease received insulin or other bovine derived product
- PD-12-44 Received growth hormone (derived from human pituitary glands)
- PD-12-45 Received finasteride (Proscar or Propecia), Tegison, Accutane,

Avodart, Jalyn, or Absorica

- PD-12-46 Received medication or antibiotics
- PD-12-47 Received vaccine or immune globulin
- PD-12-48 Exposure to a disease
- PD-12-49 Incarcerated
- PD-12-50 Resided in a rehabilitation center or psychiatric hospital
- PD-12-53 Multiple high risk behaviors/contacts
- PD-12-54 Positive drug screen

PD-12-55 Deferred by another center – reason unknown {reason for deferral unknown or not provided by the other center – use more specific PD code if reason known}

PD-12-56 Travel to leishmania risk area {e.g., Baghdad, Tikrit, Ramadi}

PD-12-57 Travel to leishmania and malarial endemic area {e.g., Afghanistan, Iraq (except Baghdad, Tikrit, Ramadi}

PD-12-58 Risk factor associated with Chagas

PD-12-59 Donor received tattoo and/or piercing {includes tattoo, any type of piercing or a combination of tattoo and/or piercing and any other type of potential blood exposure}

PD-12-60 Donor was exposed to blood or body fluids other than tattoo or piercing {includes accidental needlestick, animal bite; human bite; occupational exposure; scarification; branding; exposure not specified; multiple exposures, not including tattoo or piercing}

PD-12-61 Intimate contact with risk for a relevant transfusion-transmitted infection - HIV

PD-12-62 Intimate contact with risk for a relevant transfusion-transmitted infection - HTLV

PD-12-63 Intimate contact with risk for a relevant transfusion-transmitted infection - HBV

PD-12-64 Intimate contact with risk for a relevant transfusion-transmitted infection - HCV

PD-12-65 Intimate contact with risk for a relevant transfusion-transmitted infection - hepatitis, not specified

PD-12-66 Intimate contact with risk for a relevant transfusion-transmitted infection – Other

A - Zika

PD-12-67 Travel to Zika risk area

PD-13-** Illness

PD-13-01 Post donation illness (not hepatitis, HIV, HTLV, STD, cancer or cold/flu related) {information not known by donor prior to donation, but diagnosed after donation; includes post donation reaction (e.g., infection) at phlebotomy site; Babesiosis; West Nile Virus, Chagas}

- A Babesiosis
- B West Nile Virus
- C Non-specific symptoms possible West Nile Virus
- D Reaction at phlebotomy site
- E Chagas
- F Fever/Diarrhea
- G Infection
- H Lyme disease
- I Mononucleosis/Epstein-Barr virus
- J Blood Disorder
- K Von Willebrand disease
- L Unknown/not specified

PD-13-02 Post donation diagnosis or symptoms of Hepatitis B, or reactive test for Hepatitis B

PD-13-03 Post donation diagnosis or symptoms of Hepatitis C, or reactive test for Hepatitis C

PD-13-04 Post donation diagnosis or symptoms of HIV, or reactive test for HIV

PD-13-05 Post donation diagnosis or symptoms of HTLV, or reactive test for HTLV

PD-13-06 Post donation diagnosis or symptoms of sexually transmitted disease, or reactive test for sexually transmitted disease

PD-13-07 Post donation diagnosis or symptoms of non-specific hepatitis, reactive test for non-specific hepatitis, or elevated liver enzymes

PD-13-10 Post donation diagnosis or possible diagnosis of Creutzfeldt-Jakob Disease *{includes variant CJD}*

PD-14-** Not specifically related to high risk behavior, unsuitable history, or post donation illness

PD-14-01 Other {does not include reports of post donation illness – use PD13** codes; includes anything not included in PD12**}

PD-14-02 Donor does not want their blood used

PD-14-03 Donated to be tested or called back for test results

DS--** DONOR SCREENING**

DS-20-** Miscellaneous

DS-20-01 Other

DS-21-** Donor did not meet acceptance criteria

DS-21-01 Other {includes inappropriate acceptance of donor with unacceptable address or no proof of an acceptable address}

DS-21-02 Hemoglobin or Hematocrit unacceptable, not documented, or testing performed incorrectly {includes use of expired reagents for hemoglobin or hematocrit}

DS-21-03 Temperature unacceptable or not documented

DS-21-04 Medical review or physical not performed or inadequate

DS-21-05 Platelet count, no documented platelet count for product

DS-21-06 Unexplained weight loss

DS-22-** Donor record incomplete or incorrect

DS-22-01 Other {includes missing donor records}

DS-22-02 Donor identification {includes donor using false identification, e.g., twins}

DS-22-03 Donor history questions {includes abbreviated questionnaire used instead of full-length questionnaire; response to educational material/AIDS questions not documented; incorrect gender specific question asked}

A - Abbreviated questionnaire used instead of full-length

B - Response to educational material/AIDS questions incorrect, not documented, or missing

C - Donor determined acceptable subsequent to distribution

D - Incorrect gender specific questions asked or incorrect answer

E - Untrained staff/staff failed competency

DS-22-04 Arm inspection

DS-22-05 Donor signature missing

DS-22-06 Confidential Unit Exclusion (CUE) procedure not performed in accordance with specifications

DS-22-07 Donor confidentiality compromised

DS-26-** Deferral screening not done or incorrectly performed, including incorrect ID used during search

DS-26-01 Donor not previously deferred {use DS2601 when the deferral file is not searched or searched using incorrect donor identification information; or the deferral file was incorrectly searched and the donor was not previously deferred}

DS-27-** Deferral screening not done or incorrectly performed, including incorrect ID used during search, prior deferral due to testing for: {use DS27** when the deferral file is not searched or searched using incorrect donor identification information, or the deferral file was incorrectly searched and the donor was previously deferred due to testing}

DS-27-01 Other

DS-27-02 HIV

DS-27-03 HBV

DS-27-04 Anti-HBc

DS-27-05 HCV

DS-27-06 Anti-HTLV

DS-27-07 ALT

DS-27-08 Syphilis

DS-27-09 ZIKV

DS-28-** Deferral screening not done or incorrectly performed, including incorrect ID used during search, prior deferral due to history {use DS28** when the deferral file is not searched or searched using incorrect donor identification information, or the deferral file was incorrectly searched and the donor was previously deferred due to history}

DS-28-01 Other {includes type of behavior or history unknown or not specified; unacceptable address; rape; donor unreliable, for example mental status questionable or donor unable to comprehend donor history questions}

DS-28-02 History of hepatitis, not specified

DS-28-03 History of jaundice

DS-28-04 History of Hepatitis B

DS-28-05 History of Hepatitis C

DS-28-06 Sexually transmitted disease

DS-28-07 Intimate contact with risk for a relevant transfusion-transmitted infection - sexually transmitted disease

DS-28-13 Non-specific intimate contact with risk for a relevant transfusion-transmitted infection *{includes contact with an individual who was deferred by }*

another center, on a national deferral list, or tested reactive for an unknown viral marker}

DS-28-14 Male donor had sex with another man

DS-28-15 Female had sex with a man who had sex with another man

DS-28-16 IV drug use not prescribed by a doctor {includes taking illegal drugs by needle, e.g., IM}

DS-28-17 Sex partner used IV drugs not prescribed by a doctor

DS-28-18 Non-IV-drug use {includes taking illegal drugs by route other than needle}

DS-28-19 Sex partner used non-IV drugs

DS-28-20 Donor lived in or immigrated from an HIV Group O risk area

DS-28-21 Sex partner lived in or immigrated from an HIV Group O risk area

DS-28-22 Exchanged sex for drugs or money

DS-28-23 Sex partner exchanged sex for drugs or money

DS-28-28 Donor received transfusion

DS-28-29 Donor received tissue allograft or transplanted organ

DS-28-36 Travel to malaria endemic area/history of malaria

DS-28-37 History of disease {donor was aware of condition or disease prior to donation; does not include diseases that do not affect the safety, purity, or potency of the product e.g., heart disease, hemochromatosis, autoimmune disorders, such as Rheumatoid Arthritis, Lupus; history of surgery is reported under DS-28-28 only if blood or blood products were received during surgery or under DS-28-29 if donor received tissue allograft or transplanted organ}

A - Babesia

B - West Nile Virus

C - Chagas

E - Fever/Diarrhea

F - Infection

G - Lyme disease

H - Mononucleosis/Epstein-Barr virus

I - Blood Disorder

J - Von Willebrand disease

K - Idiopathic Thrombocytopenic Purpura (ITP)/Thrombotic

Thrombocytopenic purpura (TTP)

L - Unknown/not specified

DS-28-40 Risk factors associated with Creutzfeldt-Jakob Disease - brain surgery

DS-28-41 Risk factors associated with Creutzfeldt-Jakob Disease - family history

DS-28-42 Risk factors associated with Creutzfeldt-Jakob Disease (vCJD) - travel

DS-28-43 Risk factors associated with Creutzfeldt-Jakob Disease - received insulin or other bovine derived product

DS-28-44 Received growth hormone (derived from human pituitary glands)

DS-28-45 Received finasteride (Proscar or Propecia), Tegison, Accutane,

Avodart, Jalyn, or Absorica

DS-28-46 Received medication or antibiotics

DS-28-47 Received vaccine or immune globulin

DS-28-48 Exposure to a disease

DS-28-49 Incarcerated

DS-28-50 Resided in a rehabilitation center or psychiatric hospital

DS-28-53 Multiple high risk behaviors/contacts

DS-28-54 Positive drug screen

DS-28-55 Deferred by another center – reason unknown {reason for deferral unknown or not provided by the other center – use more specific DS code if reason known}

DS-28-56 Travel to leishmania risk area {e.g., Baghdad, Tikrit, Ramadi}

DS-28-57 Travel to leishmania and malarial endemic area {e.g., Afghanistan, Iraq (except Baghdad, Tikrit, Ramadi}

DS-28-58 Risk factor associated with Chagas

DS-28-59 Donor received tattoo and/or piercing {includes tattoo, any type of piercing or a combination of tattoo and/or piercing and any other type of potential blood exposure}

DS-28-60 Donor was exposed to blood or body fluids other than tattoo or piercing {includes: accidental needlestick, animal bite; human bite; occupational exposure; scarification; branding; exposure not specified; multiple exposures, not including tattoo or piercing}

DS-28-61 Intimate contact with risk for a relevant transfusion-transmitted infection - HIV

DS-28-62 Intimate contact with risk for a relevant transfusion-transmitted infection - HTLV

DS-28-63 Intimate contact with risk for a relevant transfusion-transmitted infection - HBV

DS-28-64 Intimate contact with risk for a relevant transfusion-transmitted infection - HCV

DS-28-65 Intimate contact with risk for a relevant transfusion-transmitted infection - hepatitis, not specified

DS-28-66 Intimate contact with risk for a relevant transfusion-transmitted infection – Other

A - Zika

DS-28-67 Travel to Zika risk area

DS-29-** Donor gave history which warranted deferral or follow up and was not deferred or follow up questions were not asked {use DS29** when a donor gives disqualifying information during the screening process and was not appropriately deferred or provides some information that requires further questioning to determine donor eligibility and follow up questioning was not done}

DS-29-01 Other {includes type of behavior or history unknown or not specified; rape; donor unreliable, for example mental status questionable or donor unable to comprehend donor history questions; response to educational material/AIDS questions unacceptable; residency/travel outside U.S., unacceptable, discrepant or missing response to gender specific or attention question}

DS-29-02 History of hepatitis, not specified

DS-29-03 History of jaundice

DS-29-04 History of Hepatitis B

DS-29-05 History of Hepatitis C

DS-29-06 Sexually transmitted disease

DS-29-07 Intimate contact with risk for a relevant transfusion-transmitted infection - sexually transmitted disease

DS-29-13 Non-specific intimate contact with risk for a relevant transfusion-transmitted infection {includes contact with an individual who was deferred by another center, on a national deferral list, or tested reactive for an unknown viral marker}

DS-29-14 Male donor had sex with another man

DS-29-15 Female had sex with a man who had sex with another man

DS-29-16 IV drug use not prescribed by a doctor {includes taking illegal drugs by needle, e.g., IM}

DS-29-17 Sex partner used IV drugs not prescribed by a doctor

DS-29-18 Non-IV-drug use {includes taking illegal drugs by route other than needle}

DS-29-19 Sex partner used non-IV drugs

DS-29-20 Donor lived in or immigrated from an HIV Group O risk area

DS-29-21 Sex partner lived in or immigrated from an HIV Group O risk area

DS-29-22 Exchanged sex for drugs or money

DS-29-23 Sex partner exchanged sex for drugs or money

DS-29-28 Donor received transfusion

DS-29-29 Donor received tissue allograft or transplanted organ

DS-29-36 Travel to malaria endemic area/history of malaria

DS-29-37 History of disease {donor was aware of condition or disease prior to donation; does not include diseases that do not affect the safety, purity, or potency of the product e.g., heart disease, hemochromatosis, autoimmune disorders, such as Rheumatoid Arthritis, Lupus; history of surgery is reported under DS-29-28 only if blood or blood products were received during surgery or under DS-29-29 if donor received tissue allograft or transplanted organ}

A - Babesia

B - West Nile Virus

C - Chagas

E - Fever/Diarrhea

F - Infection

G - Lyme disease

H - Mononucleosis/Epstein-Barr virus

I - Blood Disorder

J - Von Willebrand disease

K - Idiopathic Thrombocytopenic Purpura (ITP) /Thrombotic

Thrombocytopenic purpura (TTP)

L - Unknown/not specified

DS-29-40 Risk factors associated with Creutzfeldt-Jakob Disease - brain surgery

DS-29-41 Risk factors associated with Creutzfeldt-Jakob Disease - family history

DS-29-42 Risk factors associated with Creutzfeldt-Jakob Disease (vCJD) - travel

DS-29-43 Risk factors associated with Creutzfeldt-Jakob Disease - received insulin or other bovine derived product

DS-29-44 Received growth hormone (derived from human pituitary glands)

DS-29-45 Received finasteride (Proscar or Propecia), Tegison, Accutane,

Avodart, Jalyn, or Absorica

DS-29-46 Received medication or antibiotics

DS-29-47 Received vaccine or immune globulin

DS-29-48 Exposure to a disease

DS-29-49 Incarcerated

DS-29-50 Resided in a rehabilitation center or psychiatric hospital

DS-29-53 Multiple high risk behaviors/contacts

DS-29-54 Positive drug screen

DS-29-55 Deferred by another center – reason unknown {reason for deferral unknown or not provided by the other center – use more specific DS code if reason known}

DS-29-56 Travel to leishmania risk area {e.g., Baghdad, Tikrit, Ramadi}

DS-29-57 Travel to leishmania and malarial endemic area {e.g., Afghanistan, Iraq (except Baghdad, Tikrit, Ramadi}

DS-29-58 Risk factor associated with Chagas

DS-29-59 Donor received tattoo and/or piercing {includes tattoo, any type of piercing or a combination of tattoo and/or piercing and any other type of potential blood exposure}

DS-29-60 Donor was exposed to blood or body fluids other than tattoo or piercing {includes accidental needlestick, animal bite; human bite; occupational exposure; scarification; branding; exposure not specified; multiple exposures, not including tattoo or piercing}

DS-29-61 Intimate contact with risk for a relevant transfusion-transmitted infection - HIV

DS-29-62 Intimate contact with risk for a relevant transfusion-transmitted infection - HTLV

DS-29-63 Intimate contact with risk for a relevant transfusion-transmitted infection - HBV

DS-29-64 Intimate contact with risk for a relevant transfusion-transmitted infection - HCV

DS-29-65 Intimate contact with risk for a relevant transfusion-transmitted infection - hepatitis, not specified

DS-29-66 Intimate contact with risk for a relevant transfusion-transmitted infection – Other

A - Zika

DS-29-67 Travel to Zika risk area

DD--** DONOR DEFERRAL**

DD-30-** Miscellaneous

DD-30-01 Other

DD-31-** Donor missing or incorrectly identified on deferral list, donor was or should have been previously deferred due to testing for {use DD31** if the donor should have been deferred due to testing at a previous donation and was either not on the deferral list

or incorrectly identified on the deferral list, e.g. listed as temporary deferral instead of permanent deferral}

DD-31-01 Other

DD-31-02 HIV

DD-31-03 HBV

DD-31-04 Anti-HBc

DD-31-05 HCV

DD-31-06 Anti-HTLV

DD-31-07 ALT

DD-31-08 Syphilis

DD-31-09 ZIKV

DD-32-** Donor missing or incorrectly identified on deferral list, donor was or should have been previously deferred due to history {use DD32** if the donor should have been deferred due to history at a previous donation and was either not on the deferral list or incorrectly identified on the deferral list, e.g. listed as temporary deferral instead of permanent deferral}

DD-32-01 Other {includes type of behavior or history unknown or not specified; unacceptable address; rape; donor unreliable, for example mental status questionable or donor unable to comprehend donor history questions}

DD-32-02 History of hepatitis, not specified

DD-32-03 History of jaundice

DD-32-04 History of Hepatitis B

DD-32-05 History of Hepatitis C

DD-32-06 Sexually transmitted disease

 $DD\mbox{-}32\mbox{-}07$ - Intimate contact with risk for a relevant transfusion-transmitted infection - sexually transmitted disease

DD-32-13 Non-specific intimate contact with risk for a relevant transfusion-transmitted infection {includes contact with an individual who was deferred by another center, on a national deferral list, or tested reactive for an unknown viral marker}

DD-32-14 Male donor had sex with another man

DD-32-15 Female had sex with a man who had sex with another man

DD-32-16 IV drug use not prescribed by a doctor {includes taking illegal drugs by needle, e.g., IM}

DD-32-17 Sex partner used IV drugs not prescribed by a doctor

DD-32-18 Non-IV-drug use {includes taking illegal drugs by route other than needle}

DD-32-19 Sex partner used non-IV drugs

DD-32-20 Donor lived in or immigrated from an HIV Group O risk area

DD-32-21 Sex partner lived in or immigrated from an HIV Group O risk area

DD-32-22 Exchanged sex for drugs or money

DD-32-23 Sex partner exchanged sex for drugs or money

DD-32-28 Donor received transfusion

DD-32-29 Donor received tissue allograft or transplanted organ

DD-32-36 Travel to malaria endemic area/history of malaria

DD-32-37 History of disease {donor was aware of condition or disease prior to donation; does not include diseases that do not affect the safety, purity, or potency of the product e.g., heart disease, hemochromatosis, autoimmune disorders, such as Rheumatoid Arthritis, Lupus; history of surgery is reported under DD-32-28 only if blood or blood products were received during surgery or under DD-32-29 if the donor received tissue allograft or transplanted organ}

- A Babesia
- B West Nile Virus
- C Chagas
- E Fever/Diarrhea
- F Infection
- G Lyme disease
- H Mononucleosis/Epstein-Barr virus
- I Blood Disorder
- J Von Willebrand disease
- K Idiopathic Thrombocytopenic Purpura (ITP) /Thrombotic Thrombocytopenic purpura (TTP)
- L Unknown/not specified
- DD-32-40 Risk factors associated with Creutzfeldt-Jakob Disease brain surgery
- DD-32-41 Risk factors associated with Creutzfeldt-Jakob Disease family history
- DD-32-42 Risk factors associated with Creutzfeldt-Jakob Disease (vCJD) travel
- DD-32-43 Risk factors associated with Creutzfeldt-Jakob Disease received insulin or other bovine derived product
- DD-32-44 Received growth hormone (derived from human pituitary glands)
- DD-32-45 Received finasteride (Proscar or Propecia), Tegison, Accutane,

Avodart, Jalyn, or Absorica

- DD-32-46 Received medication or antibiotics
- DD-32-47 Received vaccine or immune globulin
- DD-32-48 Exposure to a disease
- DD-32-49 Incarcerated
- DD-32-50 Resided in a rehabilitation center or psychiatric hospital
- DD-32-53 Multiple high risk behaviors/contacts
- DD-32-54 Positive drug screen
- DD-32-55 Deferred by another center reason unknown {reason for deferral unknown or not provided by the other center use more specific DD code if reason known}
- DD-32-56 Travel to leishmania risk area {e.g., Baghdad, Tikrit, Ramadi}
- DD-32-57 Travel to leishmania and malarial endemic area {e.g., Afghanistan, Iraq (except Baghdad, Tikrit, Ramadi}
- DD-32-58 Risk factor associated with Chagas
- DD-32-59 Donor received tattoo and/or piercing {includes tattoo, any type of piercing or a combination of tattoo and/or piercing and any other type of potential blood exposure}
- DD-32-60 Donor was exposed to blood or body fluids other than tattoo or piercing {includes accidental needlestick, animal bite; human bite; occupational

exposure; scarification; branding; exposure not specified; multiple exposures, not including tattoo or piercing}

DD-32-61 Intimate contact with risk for a relevant transfusion-transmitted

infection - HIV

DD-32-62 Intimate contact with risk for a relevant transfusion-transmitted

infection - HTLV

DD-32-63 Intimate contact with risk for a relevant transfusion-transmitted

infection - HBV

DD-32-64 Intimate contact with risk for a relevant transfusion-transmitted infection – HCV

DD-32-65 Intimate contact with risk for a relevant transfusion-transmitted infection - hepatitis, not specified

DD-32-66 Intimate contact with risk for a relevant transfusion-transmitted

infection - Other

A - Zika

DD-32-67 Travel to Zika risk area

DD-34-** Donor incorrectly deleted from deferral list or donor not reentered properly, prior deferral due to testing for {use DD34** if the donor was deferred due to testing at a previous donation and was either inappropriately removed from the deferral list or not reentered properly}

DD-34-01 Other

DD-34-02 HIV

DD-34-03 HBV

DD-34-04 Anti-HBc

DD-34-05 HCV

DD-34-06 Anti-HTLV

DD-34-07 ALT

DD-34-08 Syphilis

DD-35-** Donor incorrectly deleted from deferral list, prior deferral due to history {use DD35** if the donor was deferred due to history at a previous donation and was inappropriately removed from the deferral list}

DD-35-01 Other {includes type of behavior or history unknown or not specified; unacceptable address; rape; donor unreliable, for example mental status questionable or donor unable to comprehend donor history questions}

DD-35-02 History of hepatitis, not specified

DD-35-03 History of jaundice

DD-35-04 History of Hepatitis B

DD-35-05 History of Hepatitis C

DD-35-06 Sexually transmitted disease

DD-35-07 Intimate contact with risk for a relevant transfusion-transmitted infection - sexually transmitted disease

DD-35-13 Non-specific intimate contact with risk for a relevant transfusion-transmitted infection *(includes contact with an individual who was deferred by*

another center. on a national deferral list, or tested reactive for an unknown viral marker}

DD-35-14 Male donor had sex with another man

DD-35-15 Female had sex with a man who had sex with another man

DD-35-16 IV drug use not prescribed by a doctor {includes taking illegal drugs by needle, e.g., IM}

DD-35-17 Sex partner used IV drugs not prescribed by a doctor

DD-35-18 Non-IV-drug use {includes taking illegal drugs by route other than needle}

DD-35-19 Sex partner used non-IV drugs

DD-35-20 Donor lived in or immigrated from an HIV Group O risk area

DD-35-21 Sex partner lived in or immigrated from an HIV Group O risk area

DD-35-22 Exchanged sex for drugs or money

DD-35-23 Sex partner exchanged sex for drugs or money

DD-35-28 Donor received transfusion

DD-35-29 Donor received tissue allograft or transplanted organ

DD-35-36 Travel to malaria endemic area/history of malaria

DD-35-37 History of disease {donor was aware of condition or disease prior to donation; does not include diseases that do not affect the safety, purity, or potency of the product e.g., heart disease, hemochromatosis, autoimmune disorders, such as Rheumatoid Arthritis, Lupus; history of surgery is reported under DD-35-28 only if blood or blood products were received during surgery or under DD-35-29 if the donor received tissue allograft or transplanted organ}

A - Babesia

B - West Nile Virus

C - Chagas

E - Fever/Diarrhea

F - Infection

G - Lyme disease

H - Mononucleosis/Epstein-Barr virus

I - Blood Disorder

J - Von Willebrand disease

K - Idiopathic Thrombocytopenic Purpura (ITP) /Thrombotic

Thrombocytopenic purpura (TTP)

L - Unknown/not specified

DD-35-40 Risk factors associated with Creutzfeldt-Jakob Disease - brain surgery

DD-35-41 Risk factors associated with Creutzfeldt-Jakob Disease - family history

DD-35-42 Risk factors associated with Creutzfeldt-Jakob Disease (vCJD) - travel

DD-35-43 Risk factors associated with Creutzfeldt-Jakob Disease - received insulin or other bovine derived product

DD-35-44 Received growth hormone (derived from human pituitary glands)

DD-35-45 Received finasteride (Proscar or Propecia), Tegison, Accutane,

Avodart, Jalyn, or Absorica

DD-35-46 Received medication or antibiotics

DD-35-47 Received vaccine or immune globulin

DD-35-48 Exposure to a disease

DD-35-49 Incarcerated

DD-35-50 Resided in a rehabilitation center or psychiatric hospital

DD-35-53 Multiple high risk behaviors/contacts

DD-35-54 Positive drug screen

DD-35-55 Deferred by another center – reason unknown {reason for deferral unknown or not provided by the other center – use more specific DD code if reason known}

DD-35-56 Travel to leishmania risk area {e.g., Baghdad, Tikrit, Ramadi}

DD-35-57 Travel to leishmania and malarial endemic area {e.g., Afghanistan, Iraq (except Baghdad, Tikrit, Ramadi}

DD-35-58 Risk factor associated with Chagas

DD-35-59 Donor received tattoo and/or piercing {includes tattoo, any type of piercing or a combination of tattoo and/or piercing and any other type of potential blood exposure}

DD-35-60 Donor was exposed to blood or body fluids other than tattoo or piercing {includes accidental needlestick, animal bite; human bite; occupational exposure; scarification; branding; exposure not specified; multiple exposures, not including tattoo or piercing}

DD-35-61 Intimate contact with risk for a relevant transfusion-transmitted infection - HIV

DD-35-62 Intimate contact with risk for a relevant transfusion-transmitted infection - HTLV

DD-35-63 Intimate contact with risk for a relevant transfusion-transmitted infection - HBV

DD-35-64 Intimate contact with risk for a relevant transfusion-transmitted infection - HCV

DD-35-65 Intimate contact with risk for a relevant transfusion-transmitted infection - hepatitis, not specified

DD-35-66 Intimate contact with risk for a relevant transfusion-transmitted infection – Other

A - Zika

DD-35-67 Travel to Zika risk area

BC-**-** BLOOD COLLECTION

BC-40-** Miscellaneous

BC-40-01 Other

BC-41-** Sterility compromised

BC-41-01 Other

BC-41-02 Bacterial contamination (identify organism if possible) {use BC4102 if contamination is discovered as a result of a patient transfusion reaction; if product was prepared in an open system (e.g. pooled Platelets), use CP5102; if contamination was found during Bacterial Detection Testing, use QC9216}

A - Staphylococcus coagulase negative

B - Gram positive cocci

C - Staphylococcus epidermidis

- D Propionibacterium acnes
- E Staphylococcus aureus
- F Organism not identified or specified

BC-41-03 Air contamination {system open during collection process, e.g., during sample collection}

BC-41-04 Arm prep not performed or performed inappropriately {includes the use of incorrect arm preparation supplies; supplies not maintained appropriately, e.g. stored at unacceptable temperature}

BC-42-** Collection bag

BC-42-01 Other

BC-42-02 Blood drawn into outdated bag

BC-42-03 Incorrect anticoagulant

BC-42-04 Outdated anticoagulant

BC-42-05 Potential collection set (bag, tubing) defect (e.g., product leaking) {use BC4205 if event not related to component preparation}

BC-42-06 Incorrect collection bag used (e.g., 500 ml bag instead of 450ml bag)

BC-43-** Collection process

BC-43-01 Other {includes use of incorrect collection supplies; use of supplies that were not maintained appropriately; product contained clots and was hemolyzed which was not discovered prior to distribution}

BC-43-02 Collection time extended, discrepant, or not documented; not discovered prior to component preparation

BC-43-03 Overbleed; not discovered prior to component preparation

BC-43-04 Collection status not documented or discrepant

BC-43-05 Product contained clots or fibrin, not discovered prior to distribution {includes clots discovered by consignee upon receipt of product or during transfusion}

BC-43-06 Product hemolyzed, not discovered prior to distribution {reporting not required if hemolyzed product discovered after consignee accepted it into their inventory}

BC-43-07 Source Plasma from two different donors pooled into one pooling bottle

BC-43-08 Donor sample tube mix-up or donor sample tube mislabeled

BC-43-09 Apheresis collection process

BC-44-** Apheresis collection device

BC-44-01 Other {includes collection kits not used within acceptable time period (or not documented) after loading or priming}

BC-44-02 Device defect

BC-44-03 Softgoods defect (bags, tubing, etc)

CP--** COMPONENT PREPARATION**

CP-50-** Miscellaneous

CP-50-01 Other

CP-51-** Sterility compromised

CP-51-01 Other

CP-51-02 Bacterial contamination (identify organism if possible) {use CP5102 if the contamination may be related to products prepared in an open system, e.g., pooled, washed, deglycerolized; if contamination is discovered during Bacterial Detection testing, use QC9216}

A - Staphylococcus coagulase negative

CP-51-03 Air contamination

CP-51-04 Product integrity compromised during component preparation (e.g., leaking at sterile connection site)

CP-52-** Component not prepared in accordance with specifications

CP-52-01 Other {includes insufficient or excessive plasma volume}

CP-52-02 Platelets made from Whole Blood collected from donor who took medication that may affect platelet function

CP-52-03 Resting time requirements not met for Platelets

CP-52-04 Platelets not agitated

CP-52-05 Platelet count or platelet yield not acceptable as a result of a component preparation deviation or unexpected event {includes platelet count too high to store in one bag or platelet count too low to store in multiple bags}

CP-52-06 Processed at incorrect centrifuge setting

CP-52-07 Product not frozen within the appropriate time frame or freezing time not documented

CP-52-08 Product prepared at incorrect temperature or held at incorrect temperature during component preparation

CP-52-09 Washing/deglycerolization not performed in accordance with specifications {includes expired saline or incorrect wash solution used}

CP-52-10 Leukoreduction not performed in accordance with specifications {includes time component returned to controlled temperature not documented or discrepant; product not leukoreduced within allowable time frame; filtration process incomplete or performed incorrectly}

CP-52-11 Irradiation not performed in accordance with specifications {includes time component returned to controlled temperature not documented or discrepant; documentation of irradiation process incomplete; product irradiated more than once; irradiation process incomplete or inadequate}

CP-52-12 Components not prepared within appropriate time frame after collection

CP-52-13 Additive solution not added, added incorrectly, or added to incorrect product or expired additive solution added

CP-52-14 Thawing frozen product not performed in accordance with specifications

CP-52-15 Pooling not performed in accordance with specifications {includes incorrect number of units pooled}

CP-52-16 Aliquot preparation not performed in accordance with specifications

CP-52-17 Sterile docking procedure not performed in accordance with specifications {includes incorrect, missing, or discrepant documentation of weld inspection}

CP-52-18 Pathogen reduction not performed in accordance with specifications

CP-53-** Component prepared from a unit that was

CP-53-01 Other

CP-53-02 Overweight

CP-53-03 Underweight

CP-53-04 Collected or stored at unacceptable or undocumented temperature

CP-53-05 A difficult collection or had an extended collection time

CP-53-06 Collected from a donor with potential TRALI risk

CP-54-** Component manufactured that was

CP-54-01 Other

CP-54-02 Overweight

CP-54-03 Underweight

CP-54-04 Lipemic

CP-54-05 Bloody

VT/RT LABORATORY TESTING

VT-**-** RELEVANT TRANSFUSION-TRANSMITTED INFECTION TESTING

VT-70-** Miscellaneous

VT-70-01 Other

VT-71-** Testing performed, interpreted or documented incorrectly (includes QC not performed or unacceptable) for {use VT71** only if testing was performed, interpreted or documented incorrectly; use QC92** if testing is positive or use QC93** if testing is not performed, incompletely performed, or not documented}

VT-71-00 Other

VT-71-01 HBV

VT-71-02 HIV

VT-71-06 Syphilis

VT-71-07 HTLV

VT-71-09 ALT

VT-71-10 HCV

VT-71-11 More than 1 test, e.g., all viral markers

VT-71-12 Cytomegalovirus

VT-71-15 Multiplex Nucleic Acid Test (NAT)

VT-71-17 West Nile Virus

VT-71-18 T. Cruzi (Chagas)

VT-71-19 Bacterial testing

VT-71-20 ZIKV

VT-72-** Sample identification

VT-72-01 Other

VT-72-02 Incorrect sample tested

VT-72-03 Sample used for testing was incorrectly or incompletely labeled

VT-72-04 Unsuitable sample used for testing

RT--** ROUTINE TESTING**

RT-60-** Miscellaneous

RT-60-01 Other

RT-61-** Testing performed, interpreted, or documented incorrectly for {use RT61** only if testing was performed, interpreted or documented incorrectly; use QC92** if testing positive or use QC93** if testing is not performed, incompletely performed or not documented}

RT-61-01 Other {includes DAT; Hemoglobin S testing}

A - Hemoglobin S

B - Isohemagglutinin titers

RT-61-04 ABO and/or Rh

RT-61-05 Antibody screening or identification

RT-61-06 Antigen typing

RT-61-07 Platelet count

RT-61-08 Compatibility {includes electronic or immediate spin crossmatch performed instead of full crossmatch, when required}

RT-61-09 ABO, Rh, and antibody screen

RT-61-10 ABO, Rh, antibody screen, and compatibility

RT-61-11 Antibody screen and compatibility

RT-62-** Sample identification

RT-62-01 Other

RT-62-02 Incorrect sample tested

RT-62-03 Sample used for testing was incorrectly or incompletely labeled

RT-62-04 Unsuitable sample used for testing (e.g., too old)

RT-63-** Testing performed using reagents in which QC was unacceptable, not performed, not documented, or expired reagents were used

RT-63-01 Other

RT-63-04 ABO and/or Rh

RT-63-05 Antibody screening or identification

RT-63-06 Antigen typing

RT-63-07 Multiple testing {includes all routine testing}

RT-63-08 Coombs control cells

LA-**-** LABELING

LA-80-** Miscellaneous

LA-80-01 Other

LA-81-** Labels applied to blood unit or product incorrect or missing information

LA-81-01 Other {includes units collected from a paid donor labeled as collected from a volunteer donor}

LA-81-02 ABO and/or Rh incorrect or missing

LA-81-04 Product type or code incorrect or missing (e.g., RBC labeled as Whole

Blood) {do not use LA8104 if there is a specific code available, e.g. use LA8113 if unit not labeled as leukoreduced}

LA-81-06 Expiration date or time extended or missing

LA-81-08 Anticoagulant incorrect or missing (e.g., CPD vs ACD)

LA-81-09 Donor/unit number or lot number incorrect or missing

LA-81-10 Combination of incorrect or missing information {e.g., unit number and expiration date}

LA-81-11 Product or anticoagulant volume or weight incorrect or missing

LA-81-12 Irradiation status incorrect or missing

LA-81-13 Leukoreduction status incorrect or missing

LA-81-14 Irradiation and leukoreduction status incorrect or missing

LA-81-15 CMV status incorrect or missing

LA-81-16 Machine-readable bar code incorrect or missing {Lot number, product code, or ABO and Rh of the donor}

LA-82-** Crossmatch tag, tie tag or transfusion record incorrect or missing information {Use LA-82 if tag physically attached to the unit is incorrect or missing information, the transfusion record, accompanied with unit, is incorrect or missing information, or both the tag and transfusion record are incorrect or missing information}

LA-82-01 Other {includes Hemoglobin S; required information that's not identified in any other deviation code}

A - Hemoglobin S

LA-82-02 Unit ABO and/or Rh incorrect or missing

LA-82-03 Recipient ABO and/or Rh incorrect or missing

LA-82-04 Product type or code incorrect or missing

LA-82-05 Expiration date or time extended or missing

LA-82-06 Unit, lot or pool number incorrect or missing

LA-82-07 Recipient identification incorrect or missing

LA-82-08 Antigen incorrect or missing

LA-82-09 Antibody incorrect or missing

LA-82-10 Platelet count incorrect or missing

LA-82-11 HLA type incorrect or missing

LA-82-12 Product or anticoagulant volume or weight incorrect or missing

LA-82-13 CMV status incorrect or missing

LA-82-14 Irradiation status incorrect or missing

LA-82-15 Leukoreduced status incorrect or missing

LA-82-16 Crossmatch tags or transfusion records switched, both units intended for the same patient

LA-82-17 Compatibility information incorrect or missing

LA-82-18 Biohazard or test status incorrect or missing {includes autologous unit with a positive viral marker not labeled appropriately}

LA-82-19 Combination of incorrect or missing information {e.g., unit number and expiration date}

LA-82-20 Crossmatch tag, tie tag, or transfusion record missing or attached to incorrect unit {e.g., intended for different patient}

QC-**-** QUALITY CONTROL and DISTRIBUTION

QC-90-** Miscellaneous QC-90-01 Other

QC-91-** Failure to quarantine unit due to medical history {includes failure to quarantine after receiving post donation information, use the code specific to the post donation information}

QC-91-01 Other {includes type of behavior or history unknown or not specified; unacceptable address; rape; donor unreliable, for example mental status questionable or donor unable to comprehend donor history questions}

QC-91-02 History of hepatitis, not specified

QC-91-03 History of jaundice

QC-91-04 History of Hepatitis B

QC-91-05 History of Hepatitis C

QC-91-06 Sexually transmitted disease

QC-91-07 Intimate contact with risk for a relevant transfusion-transmitted infection - sexually transmitted disease

QC-91-13 Non-specific intimate contact with risk for a relevant transfusion-transmitted infection {includes contact with an individual who was deferred by another center, on a national deferral list, or tested reactive for a viral marker}

QC-91-14 Male donor had sex with another man

QC-91-15 Female had sex with a man who had sex with another man

QC-91-16 IV drug use not prescribed by a doctor {includes taking illegal drugs by needle, e.g., IM}

QC-91-17 Sex partner used IV drugs not prescribed by a doctor

QC-91-18 Non-IV-drug use {includes taking illegal drugs by route other than needle}

QC-91-19 Sex partner used non-IV drugs

QC-91-20 Donor lived in or immigrated from an HIV Group O risk area

QC-91-21 Sex partner lived in or immigrated from an HIV Group O risk area

QC-91-22 Exchanged sex for drugs or money

QC-91-23 Sex partner exchanged sex for drugs or money

QC-91-28 Donor received transfusion

QC-91-29 Donor received tissue allograft or transplanted organ

QC-91-36 Travel to malaria endemic area/history of malaria

QC-91-37 History of disease {donor was aware of condition or disease **prior** to donation; does not include diseases that do not affect the safety, purity, or potency of the product e.g., heart disease, hemochromatosis, autoimmune disorders, such as Rheumatoid Arthritis, Lupus; history of surgery is reported under QC-91-28 only if blood or blood products were received during surgery or under QC-91-29 if donor received tissue allograft or transplanted organ}

- A Babesia
- B West Nile Virus
- C Chagas
- E Fever/Diarrhea
- F Infection
- G Lyme disease
- H Mononucleosis/Epstein-Barr virus
- I Blood Disorder
- J Von Willebrand disease
- K Idiopathic Thrombocytopenic Purpura (ITP) /Thrombotic Thrombocytopenic purpura (TTP)
- L Unknown/not specified
- QC-91-39 History of Creutzfeldt-Jakob Disease
- QC-91-40 Risk factors associated with Creutzfeldt-Jakob Disease brain surgery
- QC-91-41 Risk factors associated with Creutzfeldt-Jakob Disease family history
- QC-91-42 Risk factors associated with Creutzfeldt-Jakob Disease (vCJD) travel
- QC-91-43 Risk factors associated with Creutzfeldt-Jakob Disease received insulin or other bovine derived product
- QC-91-44 Received growth hormone (derived from human pituitary glands)
- QC-91-45 Received finasteride (Proscar or Propecia), Tegison, Accutane,

Avodart, Jalyn, or Absorica

- QC-91-46 Received medication or antibiotics
- QC-91-47 Received vaccine or immune globulin
- QC-91-48 Exposure to a disease
- QC-91-49 Incarcerated
- QC-91-50 Resided in a rehabilitation center or psychiatric hospital
- QC-91-53 Multiple high risk behaviors/contacts
- OC-91-54 Positive drug screen
- QC-91-55 Deferred by another center reason unknown {reason for deferral unknown or not provided by the other center use more specific QC code if reason known}
- QC-91-56 Post donation illness
- QC-91-57 Travel to leishmania risk area {e.g., Baghdad, Tikrit, Ramadi}
- QC-91-58 Travel to leishmania and malarial endemic area {e.g., Afghanistan, Iraq (except Baghdad, Tikrit, Ramadi}
- QC-91-59 Risk factor associated with Chagas
- QC-91-60 Donor received tattoo and/or piercing {includes tattoo, any type of piercing or a combination of tattoo and/or piercing and any other type of potential blood exposure}
- QC-91-61 Donor was exposed to blood or body fluids other than tattoo or piercing {includes accidental needlestick, animal bite; human bite; occupational exposure; scarification; branding; exposure not specified; multiple exposures, not including tattoo or piercing}
- QC-91-62 Intimate contact with risk for a relevant transfusion-transmitted infection HIV

QC-91-63 Intimate contact with risk for a relevant transfusion-transmitted infection - HTLV

QC-91-64 Intimate contact with risk for a relevant transfusion-transmitted infection - HBV

QC-91-65 Intimate contact with risk for a relevant transfusion-transmitted infection - HCV

QC-91-66 Intimate contact with risk for a relevant transfusion-transmitted infection - hepatitis, not specified

QC-91-67 Intimate contact with risk for a relevant transfusion-transmitted infection – Other

A - Zika

QC-91-68 Travel to Zika risk area

QC-92-** Positive testing for {Use RT61** or VT71** if testing was performed incorrectly, use QC93** if testing was not performed, incompletely performed or not documented}

QC-92-01 Other {includes Hemoglobin S; drug screen; West Nile Virus; Parvovirus, Babsia; Chagas; DAT}

- A Hemoglobin S
- B Drug Screen
- C West Nile Virus
- D Parvovirus
- E Drug Screen and antibody screen
- F Babesia
- G Chagas
- H DAT
- I Fetal screen
- J HLA antibody
- K Isohemagglutinin titer
- OC-92-02 HIV
- QC-92-03 HBV (HBsAg, HBV NAT)
- OC-92-04 Anti-HBc
- QC-92-05 HCV (Anti-HCV, HCV NAT)
- QC-92-06 Anti-HTLV
- QC-92-07 ALT elevated
- QC-92-10 Antibody screen or identification (donor/unit or recipient)
- QC-92-11 Antigen screen
- QC-92-12 Syphilis
- QC-92-13 All viral markers
- QC-92-14 Compatibility
- QC-92-15 Multiplex Nucleic Acid Test (NAT)
- QC-92-16 Bacterial testing (identify organism if possible)
 - A Staphylococcus coagulase negative
 - B Gram positive cocci
 - C Staphylococcus epidermidis
 - D Propionibacterium acnes

- E Staphylococcus aureus
- F Bacillus species
- G Corynebacterium species
- H Streptococcus bovis

QC-92-17 ZIKV

QC-93-** Testing not performed, incompletely performed or not documented for {use RT61** or VT** if testing was performed incorrectly, use QC92** if testing was positive}

QC-93-01 Other {includes; Sickle Cell protocol; drug screen; West Nile Virus; Parvovirus, DAT, HLA antibodies}

- A Sickle Cell protocol
- B Drug screen
- C West Nile Virus
- D Parvovirus
- E Drug Screen and antibody screen
- F Babesia
- G Chagas
- H DAT
- I Fetal screen
- J HLA antibodies
- K Isohemagglutinin titer
- QC-93-02 HIV
- QC-93-03 HBV (HBsAg, HBV NAT)
- QC-93-04 Anti-HBc
- QC-93-05 HCV (anti-HCV, HCV NAT)
- QC-93-06 Anti-HTLV
- OC-93-07 ALT
- QC-93-10 Antibody screen or identification (donor/unit or recipient)
- QC-93-11 Antigen screen {use QC9311 if patient has history of positive antibody screen and unit is not screened for corresponding antigen}
- QC-93-12 Syphilis
- QC-93-13 All viral markers
- QC-93-14 Compatibility
- QC-93-15 Multiplex Nucleic Acid Test (NAT)
- QC-93-16 ABO and/or Rh (donor/unit or recipient)
- QC-93-17 ABO/Rh and antibody screen (donor/unit or recipient)
- QC-93-18 Bacterial testing
- QC-93-19 ZIKV

QC-94-** Distribution of product that did not meet specifications

QC-94-01 Other {includes inappropriate release of Rh Immune Globulin; product distributed prior to required record review}

- QC-94-02 Outdated product
- QC-94-03 Autologous unit not meeting homologous criteria

QC-94-04 Product QC unacceptable, not performed, not documented, or incomplete {includes platelet count; product hematocrit/hemoglobin; RBC recovery; absolute red cell volume or product volume; WBC count; pH; product QC not performed during validation of apheresis machine}

- A Platelet count
- B Hematocrit/Hemoglobin
- C RBC recovery
- D Volume
- E WBC count
- F-pH
- H Product QC not performed during validation of apheresis machine
- I Multiple parameters
- J Factor VIII
- K Granulocyte count

QC-94-05 Product in which specification other than QC not met {includes incorrect dose (e.g., single unit vs. pooled unit); age of product; appearance, foreign object or particulates}

QC-94-06 Product in which instrument QC, calibration, or validation was unacceptable, incomplete, not performed or not documented {includes hemoglobin/hematocrit reagents; microhematocrit centrifuge; trip scale; collection device; incubator/heat block; waterbath; centrifuge; irradiator}

- A Hemoglobin/Hematocrit reagents, Hematostat, Hemocue, mirohematocrit centrifuge
- C Trip scale
- D Collection device
- E Incubator/heat block
- F Centrifuge
- G Irradiator
- H Waterbath
- I Hematology analyzer/cell counter
- J pH meter
- K Sterile connecting device
- L Donor screening thermometer
- M Cell washer
- N Scale
- O Multiple instruments
- P Immunohematology instrument/analyzer

QC-94-08 Product distributed prior to resolution of discrepancy {conflicting information that requires investigation which is not resolved prior to distribution, e.g., discrepant test results, ABO discrepancy, Whole Blood Number discrepancy; do not use QC9408 if more specific code applies, such as QC9412 through QC9418}

- A Other
- B ABO/Rh discrepancy
- C Transfusion order/request and blood bank computer information discrepant

- D WBN discrepancy
- E Product released with quarantine tag
- F Sample tube discrepancy

QC-94-09 Product associated with product that contained clots or hemolysis {use QC9409 if in-house component is discovered to be clotted or hemolyzed and associated component has already been distributed; use QC9412 if in-house component is discovered to be clotted or hemolyzed and associated product was not quarantined; if consignee discovers component is clotted or hemolyzed and associated components were also distributed, use BC4305 (clotted) or BC4306 (hemolyzed)}

QC-94-12 Product identified as unsuitable due to a collection deviation or unexpected event {event discovered prior to distribution, but failed to quarantine product; includes collection time extended, discrepant, or not documented, potential air contamination, unit or associated unit was clotted or hemolyzed}

- A Collection time extended, discrepant or not documented
- B Potential air contamination
- C Arm preparation/inspection not performed or documented or performed incorrectly
- D Unacceptable unit weight
- E Unit or associated unit was clotted or hemolyzed
- QC-94-13 Product identified as unsuitable due to a component preparation deviation or unexpected event {event discovered prior to distribution, but failed to quarantine product; includes lekoreduction or irradiation not performed in accordance with specifications; transport (from collection center) conditions unacceptable, not documented, or discrepant}
 - A Leukoreduction procedures not performed in accordance with specifications
 - B Irradiation procedures not performed in accordance with specifications
 - C Sterile docking procedures not performed in accordance with specifications
- D Transport conditions unacceptable, not documented, or discrepant QC-94-14 Product identified as unsuitable due to a labeling deviation or unexpected event {event discovered prior to distribution, but failed to quarantine product}
- QC-94-15 Product identified as unsuitable due to a donor screening deviation or unexpected event [event discovered prior to distribution, but failed to quarantine product; includes donor history question not answered or incomplete; abbreviated donor history questionnaire used instead of full-length]
 - A Donor history question not answered, incomplete, or unacceptable
 - B Abbreviated donor history questionnaire used instead of full-length
 - C Hemoglobin/Hematocrit unacceptable, not documented, or discrepant
 - D Donor temperature unacceptable, not documented, or discrepant
 - E Incorrect gender-related questions
 - F Arm inspection

QC-94-16 Product identified as unsuitable due to a donor deferral deviation or unexpected event {event discovered prior to distribution, but failed to quarantine product}

QC-94-17 Product identified as unsuitable due to a shipping or storage deviation or unexpected event {event discovered prior to distribution, but failed to quarantine product; includes temperature excursions, shipping time out of specification}

- A Product stored at unacceptable conditions
- B No documentation of acceptable storage or shipping temperatures
- C Product released prior to 60 day hold

QC-94-18 Product identified as unsuitable due to a relevant transfusion-transmitted infection testing deviation or unexpected event {event discovered prior to distribution, but failed to quarantine product; includes products released with positive or incomplete testing, e.g., HBV, HCV, HIV, bacterial testing, ZIKV}

A - Bacterial testing

QC-96-** Shipping and storage

QC-96-01 Other

QC-96-02 Arrived at consignee at unacceptable temperature {use this code if shipment was packed appropriately, but the temperature upon arrival was unacceptable}

QC-96-03 Stored at incorrect temperature

QC-96-04 No documentation that product was shipped or stored at appropriate temperature

QC-96-05 Temperature not recorded or unacceptable upon return, unit redistributed

QC-96-06 Shipment exceeded time allowed for shipping

QC-96-07 Product not packed in accordance with specifications or no documentation that product was packed appropriately

QC-96-08 Product returned to blood center and reissued inappropriately {includes no record of inspection upon return; if specific to temperature, use QC-96-05} QC-96-09 Visual inspection not performed or documented by blood center prior to distribution

QC-97-** Distribution procedure not performed in accordance with blood bank transfusion service's specifications

OC-97-01 Other

QC-97-02 Product not irradiated as required

QC-97-03 Product issued to wrong patient

QC-97-04 Improper product selected for patient {e.g., FFP issued instead of RBC; use more specific codes, such as QC-93-11 if specific typing is not performed; use QC-04-05 if incorrect dose (e.g., single unit vs. pooled unit) or incorrect age of product (e.g., not fresh) is issued}

QC-97-05 Improper ABO or Rh type selected for patient

QC-97-06 Product not leukoreduced as required

QC-97-07 Product released prior to obtaining current sample for ABO, Rh, antibody screen and/or compatibility testing

QC-97-08 Product not CMV negative as required

QC-97-10 Filter not issued with product or incorrect filter issued

QC-97-11 Product not irradiated and leukoreduced as required

QC-97-12 Product not irradiated and CMV negative as required

QC-97-13 Procedure for issuing not performed or documented in accordance with specifications; use QC9719 if product not issued in computer {includes request slip labeled with incorrect or missing patient identification; emergency release procedure not followed}

QC-97-14 ABO and/or Rh retype of unit not performed or performed incorrectly

QC-97-15 Visual inspection not performed, not documented, or inadequate

QC-97-16 Product inspected and accepted upon receipt from blood center, subsequently discovered to be hemolyzed

QC-97-17 Product not washed as required

QC-97-18 Product returned and reissued inappropriately

QC-97-19 Product not documented or incorrectly documented as issued in the computer (computer documentation is final check of issue process)

QC-97-20 Product not volume reduced as required

QC-97-21 Product not hemoglobin S negative as required

MI-**-** MISCELLANEOUS

MI-00-** Miscellaneous

MI-00-01 Other

MI-01-** Donor implicated in relevant transfusion-transmitted disease

MI-01-01 Other

MI-01-02 HIV

MI-01-03 Hepatitis (specify type, if known)

A - HBV

B-HCV

MI-01-04 West Nile Virus

MI-01-05 Babesia

MI-01-06 Chagas

MI-01-07 Malaria

MI-02-** Lookback; subsequent unit tested confirmed positive for {use MI02** when confirmatory or additional supplemental testing is positive; if confirmatory or additional supplemental testing is not positive, a report is not required}

MI-02-01 Other {multiple markers}

A - HIV and HBV

B - HIV and HCV

C - HBV and HCV

MI-02-02 HIV

A - HIV-2

MI-02-03 HBV

Attachment 2 – FY17: List of BPD Codes for Blood and Source Plasma Establishments

A - Anti-HBc positive MI-02-04 HCV

MI-02-05 West Nile Virus

MI-02-06 HTLV

MI-02-07 Babesia

MI-02-08 Chagas